Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has received allowance of its patent application in India covering its lead dermatology agent, PH-10, along with a number of related agents.
Subscribe to our email newsletter
The pending patent covers topical products for treatment of skin diseases such as psoriasis and eczema. The company said that, additionally, a range of active compounds are protected, each related to the active ingredient in PH-10.
Craig Dees, CEO of Provectus, said: “Coming on the heels of our recent patent in India for PV-10, our lead oncology agent, this pending patent for PH-10 is yet another major milestone for us since it secures access to a market that represents roughly one-fifth of the world’s population. Moreover, since the Indian pharmaceutical industry is becoming an important player in the global marketplace, this patent will afford Provectus the right of ownership for products sold or made in India.”